Nat Med:过量鞘脂合成会引起儿童肌萎缩侧索硬化

2021-06-01 xiaozeng MedSci原创

肌萎缩侧索硬化(ALS)是一种散发性或遗传性的进行性神经退行性疾病,ALS患者的发病年龄、运动神经元变性模式和疾病进展差异很大。

肌萎缩侧索硬化(ALS)是一种散发性或遗传性的进行性神经退行性疾病,ALS患者的发病年龄、运动神经元变性模式和疾病进展差异很大。

除了通常在55至75岁之间出现的更常见的散发性ALS之外,具有单基因遗传性致病突变是越来越多的家族性和早发性ALS病例的一大基础特征。其可为疾病提供独特的机制和病理生理学见解,并可指导合理的治疗策略的制定。

虽然ALS的发病机制涉及多种细胞过程,但迄今为止尚未发现单基因代谢紊乱与ALS之间的相关性。


在该研究中,研究人员发现,能够导致无限制的鞘脂合成的SPTLC1突变体,会诱发单基因突变型ALS。研究人员在七个表现为儿童期ALS的家系中确定了四种特定的、显性的SPTLC1突变体。

儿童期ALS患者的SPTLC1突变信息

这些突变破坏了ORMDL蛋白对SPT(丝氨酸棕榈酰转移酶)的正常稳态调节,导致SPT活性不受调节以及经典SPT产物水平的升高。值得注意的是,通过比对SPTLC1突变体的形成,研究人员发现,SPT改变的氨基酸从丝氨酸转变为丙氨酸,会导致脱氧鞘脂水平的升高,并表现为遗传性感觉和自主神经病变的替代表型。


研究人员通过小干扰RNA选择性靶向SPTLC1的ALS等位基因并进行降解,能够保持正常等位基因的完整,并使体外鞘脂的水平正常化。而原发性代谢紊乱在ALS中的作用仍然未知。

ORMDL蛋白介导的SPT稳态调节

综上,该研究结果揭示,过量的鞘脂生物合成或与运动神经元相关疾病的发病机制相关。


原始出处:

Mohassel, P., Donkervoort, S., Lone, M.A. et al. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat Med (31 May 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695986, encodeId=fd87169598619, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Wed Apr 27 05:34:23 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885195, encodeId=6cb31885195fb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 28 11:34:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503172, encodeId=38e515031e288, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523472, encodeId=5b8115234e299, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611079, encodeId=d5d916110e954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970222, encodeId=66519e0222c4, content=已读,真是受益匪浅呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 02 07:02:31 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970171, encodeId=61749e017141, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c492441509, createdName=123d6f12m66暂无昵称, createdTime=Tue Jun 01 21:43:02 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2022-04-27 chendoc252
  2. [GetPortalCommentsPageByObjectIdResponse(id=1695986, encodeId=fd87169598619, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Wed Apr 27 05:34:23 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885195, encodeId=6cb31885195fb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 28 11:34:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503172, encodeId=38e515031e288, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523472, encodeId=5b8115234e299, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611079, encodeId=d5d916110e954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970222, encodeId=66519e0222c4, content=已读,真是受益匪浅呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 02 07:02:31 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970171, encodeId=61749e017141, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c492441509, createdName=123d6f12m66暂无昵称, createdTime=Tue Jun 01 21:43:02 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2021-10-28 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1695986, encodeId=fd87169598619, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Wed Apr 27 05:34:23 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885195, encodeId=6cb31885195fb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 28 11:34:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503172, encodeId=38e515031e288, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523472, encodeId=5b8115234e299, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611079, encodeId=d5d916110e954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970222, encodeId=66519e0222c4, content=已读,真是受益匪浅呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 02 07:02:31 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970171, encodeId=61749e017141, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c492441509, createdName=123d6f12m66暂无昵称, createdTime=Tue Jun 01 21:43:02 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1695986, encodeId=fd87169598619, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Wed Apr 27 05:34:23 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885195, encodeId=6cb31885195fb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 28 11:34:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503172, encodeId=38e515031e288, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523472, encodeId=5b8115234e299, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611079, encodeId=d5d916110e954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970222, encodeId=66519e0222c4, content=已读,真是受益匪浅呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 02 07:02:31 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970171, encodeId=61749e017141, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c492441509, createdName=123d6f12m66暂无昵称, createdTime=Tue Jun 01 21:43:02 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1695986, encodeId=fd87169598619, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Wed Apr 27 05:34:23 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885195, encodeId=6cb31885195fb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 28 11:34:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503172, encodeId=38e515031e288, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523472, encodeId=5b8115234e299, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611079, encodeId=d5d916110e954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970222, encodeId=66519e0222c4, content=已读,真是受益匪浅呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 02 07:02:31 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970171, encodeId=61749e017141, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c492441509, createdName=123d6f12m66暂无昵称, createdTime=Tue Jun 01 21:43:02 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1695986, encodeId=fd87169598619, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Wed Apr 27 05:34:23 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885195, encodeId=6cb31885195fb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 28 11:34:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503172, encodeId=38e515031e288, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523472, encodeId=5b8115234e299, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611079, encodeId=d5d916110e954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970222, encodeId=66519e0222c4, content=已读,真是受益匪浅呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 02 07:02:31 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970171, encodeId=61749e017141, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c492441509, createdName=123d6f12m66暂无昵称, createdTime=Tue Jun 01 21:43:02 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2021-06-02 ms5000000518166734

    已读,真是受益匪浅呀。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1695986, encodeId=fd87169598619, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Wed Apr 27 05:34:23 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885195, encodeId=6cb31885195fb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 28 11:34:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503172, encodeId=38e515031e288, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523472, encodeId=5b8115234e299, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611079, encodeId=d5d916110e954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 03 12:34:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970222, encodeId=66519e0222c4, content=已读,真是受益匪浅呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 02 07:02:31 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970171, encodeId=61749e017141, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c492441509, createdName=123d6f12m66暂无昵称, createdTime=Tue Jun 01 21:43:02 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2021-06-01 123d6f12m66暂无昵称

    学习了

    0

相关资讯

Alzheimer's & Dementia:神经退行疾病的生物标志物“男女有别”

男性的QAlb和NfL浓度较高,且从青春期开始一生都有较高的QAlb和NfL浓度。NfL与WML无关,但QAlb与WML呈正相关。

痴呆症治疗瓶颈如何突破?两大研究带来新启示

早期发现和采取可能的干预措施在对抗AD和其他神经退行性疾病中可能具有重要意义。

Sci Adv:科学家创建出可穿透血脑屏障的药物输送纳米系统

在过去的几十年里,研究人员已经确定了导致神经退行性疾病的生物学途径,并开发了很有希望的分子靶向药物。然而,将这些发现转化为临床治疗方法的进展却慢得多,部分原因是将药物运送通过血脑屏障(BBB)是一个巨

《自然》子刊:反复轻度头部撞击可能会导致认知障碍

当频繁的轻微撞击一周后检测到在撞击结束后一个月内大脑反应发生钝化,受影响的小鼠在学习和记忆方面都表现出缺陷。

Nature: 基因疗法为无法治愈的脑部疾病带来了曙光

Nature: 基因疗法为无法治愈的脑部疾病带来了曙光

公益活动:未来可期!针对这种疾病的创新思路,或将成为神经退行性疾病治疗的曙光

编者按:随着全球人口老龄化程度的加剧,与之相关的疾病负担正在日益受到社会的重视,其中神经退行性疾病是备受关注的重点之一。全球疾病负担研究显示,目前有超过10亿人受到神经退行性疾病的影响,每年有近700